The Macaca fascicularis in preclinical efficacy evaluation

Cynomolgus macaques are anatomically and physiologically close to humans. Their similarity to humans in brain anatomy, including cerebrovasculature, make cynomolgus macaques an ideal species for preclinical neuroscience studies. In addition, because of high genetic similarity between humans and macaques, macaques are uniquely suited for evaluating efficacy of therapeutics specifically targeting human molecules of interest.

​​

Macaques are generally not used for pharmacology/efficacy screening of drug candidates:

1. Availability: Limited number of cynomolgus macaque-based disease models;

2. Expertise: Limited number of scientists and support staff experienced/skilled in NHP handling;

3. Cost: Resource intensive.

​

Solution: HPR scientists and staff have extensive experience in generating a broad range of NHP disease models and utilizing clinical relevant outcomes to measure disease progression and therapeutic efficacy. HPR will work with you in refining your study plan to ensure maximum data for the least number of animals.  

​​

Critical preclinical role of NHP models

• Efficacy outcome in a diverse, heterogeneous population, unlike rats and mice; 

• NHP models validated using, where possible, clinical standards of care;

• Biochemical parameters target molecules similar to those in humans;

• Clinically relevant outcome measures, where available. 

​​